In 2025, SGLT2 inhibitors have solidified their role as dual cardiorenal therapies, reducing heart failure hospitalizations and slowing chronic kidney disease progression across diabetic and non-diabetic patients through intraglomerular pressure reduction and natriuresis. They offer modest blood pressure lowering, enjoy expanding guideline support, and boast broad proven long-term safety profile. Read more at https://www.tumblr.com/sedna-h....ospitals/78172479976
Like
Comment
Share
